Tag: Jazz Pharmaceuticals

First Dual-Acting DNRI to Treat Daytime Sleepiness Approved by FDA

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associate...

Jazz Pharmaceuticals and Codiak to R&D Cancer Treatment

Jazz Pharmaceuticals plc and Codiak BioSciences, Inc. announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of e...

Vyxeos obtained marketing authorisation in Europe

drug-development
Jazz Pharmaceuticals announced that the European Commission approved Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion.

Jazz Pharmaceuticals and MD Anderson Cancer Center entered into collaboration

cancer-diagnostics
Jazz Pharmaceuticals and The University of Texas MD Anderson Cancer Center announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies.